Explore new discoveries in the treatment of ocular disease

LONDON - Aug. 17, 2021 - PRLog -- With 50% of the global population predicted to have complications in their sight within the next few decades, ophthalmic medicine is set to become one of the biggest industries in pharmaceuticals.

We have a great agenda for the upcoming conference in November covering hot topics on ophthalmic drug delivery, challenges and breakthroughs in drug discovery, ocular gene therapy and the future of ophthalmic drug delivery.

Download the brochure to see full agenda and speaker line-up: www.ophthalmicdrugs.com/prlog4

Keynote address: From the trabecular meshwork to the retina – Ophthalmological research at Aerie

• Update on Aerie's ROCK & combination treatments for glaucoma, including our 2021 approval in the EU and ongoing clinical trials in Japan
• Aerie's ongoing clinical and preclinical studies for retinal diseases, including the clinical programs for AR-1105, and AR-13503
• Introduction to AR-15512, a clinical candidate for Dry Eye disease
• Future outlook for glaucoma treatment and for long-term ocular dosing for the treatment of ocular disease

Mitchell De long, Vice President, Chemistry, Aerie Pharmaceuticals

Design and characteristics of a sustained release local ocular formulation of carboxyamidotriazole, a safe and effective antiangeogenic with a novel mechanism of action

• Established systemic safety in cancer trials
• Safety and effi cacy in ocular preclinical models
• Novel mechanism of action, ORAI1 inhibition
• Design and characteristics of durable local ocular formulation

Alan Franklin, CEO, ForwardVue Pharma

New mechanism of action anti-inflammatory analgesic for the treatment of ocular pain

• TA-A001: a new CB2 receptor agonist for the treatment of ocular pain and infl ammation
• SmartCelle technology to deliver TA-A001 to the eye
• SmartCelle TA-001 in preclinical models of acute pain, corneal surgery, uveitis and retinopathy

Damon smith, CEO, Tallc inc

For topical Drug Delivery to the retina — Design the right Drug

• "Purpose engineering" to design OTT166 selective integrin antagonist
• Review of preclinical research demonstrating delivery and activity of OTT166 with eye drop dosing
• Clinical research results with OTT166 in diabetic retinal disease and wAMD to date, plans for Phase 2

Kerrie Brady, Chief Executive Officer, Ocuterra Therapeutics

Register online www.ophthalmicdrugs.com/prlog4

Proudly Sponsored by Experimentica & TALLC
For media queries please contact Jinna Sidhu at hsidhu@smi-online.co.uk or call +44 (0)20 7827 6088

--END--